TXG Stock Jumps As Earnings Beat Triggers Analyst Upgrades

10x Genomics Inc. stocks have been trading up by 9.71 percent following upbeat sentiment around its latest single-cell innovations

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TXG

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For TXG Traders

Q2 2026 revenue came in at $151M, topping roughly $146.6M–$146.7M estimates and showing about 3% underlying growth once one-off patent settlement revenues are stripped out.
The company posted a Q2 loss of $0.14 per share, a narrower loss than the expected $0.24, giving TXG traders a cleaner earnings beat on both revenue and EPS.
Management nudged 2026 revenue guidance up to $610M–$630M, slightly ahead of Street expectations around $613.7M and above the prior $600M–$625M range.
Stifel doubled its TXG price target from $25 to $50 with a Buy rating, while Citi and Morgan Stanley also raised targets, showing a broad reset higher in Wall Street expectations.
TXG is leaning into growth drivers with strong early Atera demand, the Proteintech Genomics acquisition, and a multi-year cancer diagnostics collaboration with Lausanne University Hospital (CHUV).

Live Update At 12:33:01 EDT: On Monday, August 10, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 9.71%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TXG has spent the past few weeks turning a choppy chart into a momentum move. After grinding in the mid-$40s for most of late July, 10x Genomics shares broke out hard. On 2026/08/07, TXG closed at $52.03, and by 2026/08/10 it finished at $56.96 after trading as high as $57.11. That is a sharp multi-day ramp from the $42–$45 zone seen around 2026/07/20–2026/07/21.

Intraday, TXG’s latest tape shows steady, controlled buying rather than a wild squeeze. From the open around $51.91, the stock pushed above $53, then grinded higher through the mid-$50s, holding VWAP-style support near $55–$56 for most of the session. Five‑minute candles show higher lows throughout the late morning and early afternoon, a classic uptrend pattern that short-term traders watch for continuation.

More Breaking News

Under the hood, TXG is still a growth story, not a profit machine. Over the last quarter, 10x Genomics generated $151.0M in revenue but posted a net loss of $17.9M and an EBIT margin near -3%. At the same time, gross margin is a hefty 69.6% and operating cash flow was positive at about $17.0M, with free cash flow of roughly $15.4M. TXG runs with low leverage, a current ratio near 5.9, and over $500M in cash, so liquidity is not the near‑term issue. For traders, that combo — high gross margin, improving cash flow, and a still‑loss‑making P&L — screams “high‑beta growth vehicle,” which tends to react strongly around catalysts like earnings and analyst moves.

Why Traders Are Watching TXG Right Now

TXG just delivered the kind of catalyst stack active traders look for. Start with the earnings print: 10x Genomics reported Q2 2026 revenue of $151M, beating consensus estimates around $146.6M–$146.7M. EPS was a loss of $0.14 per share, but that was meaningfully better than the expected $0.24 loss. When a name like TXG beats on both the top and bottom line, the market takes notice.

Dig a little deeper and the quality of those numbers matters. On a like-for-like basis, excluding one-off patent settlement revenues from last year, TXG’s revenue grew about 3% year over year. That is not explosive, but it is real underlying growth, backed by a gross margin improvement to roughly 74% in the quarter. Management also lifted full-year 2026 guidance to $610M–$630M, up from $600M–$625M and just above the Street’s ~$613.7M mark. That tells traders management is confident enough to bake higher demand into the official plan.

The Street’s response has been just as important for TXG’s tape. Stifel doubled its price target on 10x Genomics from $25 to $50 and reiterated a Buy rating — a big reset that effectively says the prior view was too low. Citi bumped its TXG target to $50 from $45 with a Neutral stance, and Morgan Stanley raised from $37 to $40 while staying Equal Weight. Together, these moves say the bar is rising, even if not every firm is pounding the table.

On the strategic side, TXG is pushing hard into multiomics and cancer diagnostics. The company closed the Proteintech Genomics acquisition, highlighted strong early demand for its new Atera platform, and announced a multi-year collaboration with Lausanne University Hospital (CHUV) using its Flex Apex, Xenium, and Atera platforms for advanced cancer diagnostics research. That lines up neatly with a MarketsandMarkets report projecting the global multiomics market to grow from $3.18B in 2026 to $5.70B by 2031, a 12.3% CAGR. TXG is positioning itself as a core tools provider in a market that is structurally expanding, and that backdrop supports the recent re-rating.

Conclusion

TXG sits at the crossroad of strong technology, improving execution, and rising expectations. The Q2 2026 report showed 10x Genomics beating revenue and EPS forecasts, growing core business modestly, and nudging guidance higher, even while the company still runs at a net loss. Beneath the surface, TXG’s 69.6% gross margin, solid cash position, and low debt give the company room to keep funding R&D on platforms like Atera, Flex Apex, and Xenium without leaning on heavy leverage.

For traders, the price action now needs to confirm the story. TXG shares sold off about 3% after hours right after earnings, a sign that some expectations were already elevated, but the subsequent push into the high‑$50s shows dip buyers stepping in. The stair‑step intraday pattern and the breakout from the low‑$40s base give momentum traders concrete levels to trade against, both on the long and short side. That’s where trade selection matters: as Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” TXG’s recent action gives traders those pieces to evaluate in real time.

The bigger picture for TXG is tied to execution in a multiomics market projected to compound at double digits through 2031. If Atera demand continues to scale, and the Proteintech and CHUV moves translate into measurable revenue over the next few years, TXG’s current negative margins can tighten up. Until then, this remains a high‑volatility growth name where discipline is everything. As Tim Sykes loves to remind his trading community, “Cut losses quickly and don’t fall in love with a story — always let price action confirm the news.”

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!